Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Aptorum Group Ltd Cl A (APM)

Aptorum Group Ltd Cl A (APM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency Business Wire - Fri May 5, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited Business Wire - Mon May 1, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update Business Wire - Fri Apr 28, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group Business Wire - Mon Mar 27, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma Business Wire - Fri Mar 3, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus Business Wire - Fri Mar 3, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China Business Wire - Thu Mar 2, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency Business Wire - Fri Feb 10, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023 Business Wire - Mon Feb 6, 2023

Regulatory News:

APM : 0.7500 (-8.54%)
Aptorum Group Announces 1-for-10 Reverse Stock Split Business Wire - Fri Jan 20, 2023

Regulatory News:

APM : 0.7500 (-8.54%)

Barchart Exclusives

This Penny Stock Just Surged 380% on a Mega Deal. Is It a Buy, Sell, or Hold? Barchart - 5 minutes ago
LeddarTech is a beaten-down penny stock that is on the move after securing a licensing deal with a semiconductor giant. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot